ClinicalTrials.gg
RecruitingNCT06163430CARDINALUpdated Oct 15, 2026

A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)

A Phase 1/2 interventional study of MK-4208 in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase and Chronic Myeloid Leukemia, sponsored by Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Recruiting at 54 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 7 months later.
Updated Oct 15, 2026Enrollment updatedEligibility revised+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 516 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States — 48 open to participants now, 78 under way, 3 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States.

Planned enrollment
20th of 448
330 · median 36
Started
2024
with 13 others
Phase 1/2
54 of 516
2 open now
Primary completion
2029-11
later than 60 of 77 live
Registered
490th of 516
by date

Among the 516 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States, this one is the 20th largest by planned enrollment of the 448 interventional ones that give a count, is one of 14 that started in 2024, is one of 54 in phase 1/2, reaches primary completion later than 60 of the 77 other live ones, and was the 490th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

48 of the 516 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States are open now. Recruiting first, the newest first:

42 more — sign in →

All 48 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 516 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States, or all of them as a file.
02

Study summary

Researchers are looking for a new way to treat a blood cancer called chronic myeloid leukemia (CML). Researchers want to learn if MK-4208 (Tern-701) can treat this type of blood cancer.

The goal of this study is to learn about the safety of different doses (amounts) of MK-4208 (Tern-701) and if people tolerate them. Researchers also want to find the highest dose of MK-4208 (Tern-701) that people can tolerate and may work to treat blood cancer.

03

Conditions studied

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Chronic Myeloid Leukemia, Chronic Phase
  • Chronic Myeloid Leukemia

Keywords

  • allosteric inhibitor of BCR-ABL1
  • CML
  • TERN-701
  • chronic myeloid leukemia
  • T315I
  • T315I mutant
  • CARDINAL
  • HS-10382
04

Who can participate

The criteria were revised on the registry on Oct 15, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Key Inclusion Criteria:

Inclusion criteria

Inclusion Criteria include but are not limited to:

  • Have an (ECOG) performance status score of 0 to 2
  • Have an established cytopathologically confirmed diagnosis of breakpoint cluster region::Abelson (BCR-ABL1) positive Chronic Myeloid Leukemia (CML) in Chronic Phase
  • Have received treatment with at least one prior tyrosine kinase inhibitor (TKI) and have treatment failure, suboptimal response, or treatment intolerance
  • Prior treatment with asciminib is allowed
  • Adequate organ function, as assessed by local laboratory

Key Exclusion Criteria:

Exclusion criteria

Exclusion criteria include but are not limited to:

  • Systemic antineoplastic therapy (including prior TKIs, interferon-alfa, therapeutic antibodies, chemotherapy) or other experimental therapy 7 days before the first dose of MK-4208/TERN-701
  • Have completed previous anticancer therapy without resolution of all associated toxicity (to ≤ Grade 2 or baseline)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
330 participants (estimated)

Study arms

  • Experimental
    Part 1 - MK-4208 160 mg once daily (QD)

    Participants receive MK-4208 160 mg orally QD.

    Drug: MK-4208

  • Experimental
    Part 1- MK-4208 320 mg QD

    Participants receive MK-4208 320 mg orally QD.

    Drug: MK-4208

  • Experimental
    Part 1- MK-4208 400 mg QD

    Participants receive MK-4208 400 mg orally QD.

    Drug: MK-4208

  • Experimental
    Part 1- MK-4208 500 mg QD

    Participants receive MK-4208 500 mg orally QD.

    Drug: MK-4208

  • Experimental
    Part 2 - MK-4208 320 mg QD

    Participants receive MK4208 320 mg orally QD.

    Drug: MK-4208

  • Experimental
    Part 2 - MK-4208 500 mg QD

    Participants receive MK4208 500 mg orally QD.

    Drug: MK-4208

  • Experimental
    Part 2m - MK-4208 320 mg twice per day (BID)

    Participants receive MK4208 320 mg orally BID.

    Drug: MK-4208

  • Experimental
    Part 2m - MK-4208 500 mg QD

    Participants receive MK-4208 500 mg orally QD.

    Drug: MK-4208

  • Experimental
    Part 2m - MK4208 500 mg BID

    Participants receive MK4208 500 mg orally BID.

    Drug: MK-4208

  • Experimental
    Part 3 - MK-4208 500 mg QD

    Participants receive MK-4208 500 mg QD

    Drug: MK-4208

Interventions

  • 40 mg and 100 mg oral tablets

    Also known as: Tern-701, HS-10382

06

What researchers measure

Primary outcomes

  1. Part 1: Incidence of Dose Limiting Toxicities (DLTs) During the First Cycle of Intervention

    A DLT is any of a prespecified list of adverse events (AEs) of a pre-specified severity that occur during Cycle 1 (up to 28 days) if attributed to the study treatment and not attributed to any other clearly identifiable cause. The percentage of participants who experience DLTs will be reported. Each cycle is 28 days.

    Time frame: Up to 28 days

  2. Parts 1, 2m and 3: Number of Participants with at Least One AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of trial intervention, whether or not considered related to the trial intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding that is determined to be clinically significant by the investigator), symptom, or disease (new or exacerbated) temporally associated with the use of trial intervention. The number of participants with at least one AE will be reported.

    Time frame: Up to 3 years

  3. Parts 1, 2m and 3: Number of Participants with at Least One Serious Adverse Event (SAE)

    An SAE is defined as any untoward medical occurrence that, at any dose: Results in death; Is life-threatening; Requires in-patient hospitalization or prolongation of existing hospitalization; Results in persistent disability/incapacity; Is a congenital anomaly/birth defect; Other situations determined to be SAEs by the investigator. The number of participants with at least one SAE will be reported.

    Time frame: Up to 3 years

  4. Parts 1, 2m and 3: Number of Participants who Discontinued Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of trial intervention, whether or not considered related to the trial intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding that is determined to be clinically significant by the investigator), symptom, or disease (new or exacerbated) temporally associated with the use of trial intervention. The number of participants who discontinued study intervention due to an AE will be reported.

    Time frame: Up to 3 years

  5. Parts 2, 2m and 3: Number of Participants with a Complete Hematologic Response (CHR)

    The hematologic response will be evaluated by hematology and differential blood count. A CHR is defined by meeting all the following criteria and lasting for at least 4 weeks: Peripheral blood white blood cell count \< 10 × 109/L ; Peripheral blood platelet count \< 450 × 109/L; No immature cells in peripheral blood, such as myelocytes, promyelocytes, blasts and immature cells, and a basophil level \< 5%; No symptoms or signs of the disease under trial, and the palpable splenomegaly has disappeared. The number of participants with a CHR will be reported.

    Time frame: Baseline and up to 3 years

  6. Parts 2, 2m and 3: Number of Participants with a Molecular response (MR)

    The MR will be evaluated for all participants, and peripheral blood will be collected and tested for breakpoint cluster region::Abelson (BCR::ABL1/ABLIS) using real-time quantitative polymerase chain reaction performed locally and centrally with validated polymerase chain reaction technology that has a sensitivity of at least 4.5 logs. An MR is defined as follows: MR1: BCR::ABL1IS \> 1% to 10%; MR2: BCR::ABL1IS \> 0.1% to 1%; MR3 (MMR): BCR::ABL1IS \> 0.01% to 0.1%; MR4.0: BCR::ABL1IS \> 0.0032% to 0.01%; MR4.5: BCR::ABL1IS \> 0.001% to 0.0032%, MR5: ≤ 0.001%. The number of participants with a MR will be reported.

    Time frame: Baseline and up to 3 years

  7. Parts 2, 2m and 3: Number of Participants who had Best Categorical Shift in BCR-ABL1 Transcript Levels From Baseline

    The number of participants who had best categorical molecular response shift on treatment relative to baseline will be reported.

    Time frame: Baseline and up to 3 years

Secondary outcomes

  1. Parts 1, 2, 2m and 3: Trough Concentration (Ctrough) of MK-4208 in Plasma

    Ctrough is defined as the lowest concentration of study intervention after administration of the dose of intervention and prior to the next dose of intervention. Blood samples will be collected at pre-specified time points to determine the Ctough of MK-4208 in plasma.

    Time frame: Pre dose and post dose at predetermined time points up to 3 years

  2. Parts 1, 2, 2m and 3: Maximum Concentration (Cmax) of MK-4208 in Plasma

    Cmax is defined as the maximum observed concentration of study intervention in plasma after the administration of a given dose. Blood samples will be collected at pre-specified time points to determine the Cmax of MK-4208 in plasma.

    Time frame: Pre dose and post dose at predetermined time points up to 3 years

  3. Parts 1, 2, 2m and 3: Area Under the Plasma Concentration Time Curve (AUC) of MK-4208 in Plasma

    AUC is defined as the area of the plasma concentration time curve. It measures the total quantity of active intervention that effectively reaches the systemic circulation after administration of the intervention. Blood samples will be collected at pre-specified time points to determine the AUC of MK-4208 in plasma.

    Time frame: Pre dose and post dose at predetermined time points up to 3 years

  4. Parts 1, 2, 2m and 3: Oral Clearance (CL) of MK-4208 in Plasma

    CL is defined as the total intervention clearance from plasma. Blood samples will be collected at pre-specified time points to determine the CL of MK-4208 in plasma.

    Time frame: Pre dose and post dose at predetermined time points up to 3 years

  5. Parts 1, 2, 2m and 3: Time to Maximum Concentration (Tmax) of MK-4208 in Plasma

    Tmax is defined as the maximum time it takes to observe the maximum contration of study intervention in plasma after the administration of a given dose. Blood samples will be collected at pre-specified time points to determine the Tmax of MK-4208 in plasma.

    Time frame: Pre dose and post dose at predetermined time points up to 3 years

  6. Part 2: Number of Participants with at Least One AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of trial intervention, whether or not considered related to the trial intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding that is determined to be clinically significant by the investigator), symptom, or disease (new or exacerbated) temporally associated with the use of trial intervention. The number of participants with at least one AE will be reported.

    Time frame: Up to 3 years

  7. Part 2: Number of Participants with at Least One SAE

    An SAE is defined as any untoward medical occurrence that, at any dose: Results in death; Is life-threatening; Requires in-patient hospitalization or prolongation of existing hospitalization; Results in persistent disability/incapacity; Is a congenital anomaly/birth defect; Other situations determined to be SAEs by the investigator. The number of participants with at least one SAE will be reported.

    Time frame: Up to 3 years

  8. Part 2: Number of Participants who Discontinued Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of trial intervention, whether or not considered related to the trial intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding that is determined to be clinically significant by the investigator), symptom, or disease (new or exacerbated) temporally associated with the use of trial intervention. The number of participants who discontinued study intervention due to an AE will be reported.

    Time frame: Up to 3 years

  9. Part 1: Number of Participants with a CHR

    The hematologic response will be evaluated by hematology and differential blood count. A CHR is defined by meeting all the following criteria and lasting for at least 4 weeks: Peripheral blood white blood cell count \< 10 × 109/L ; Peripheral blood platelet count \< 450 × 109/L; No immature cells in peripheral blood, such as myelocytes, promyelocytes, blasts and immature cells, and a basophil level \< 5%; No symptoms or signs of the disease under trial, and the palpable splenomegaly has disappeared. The number of participants with a CHR will be reported.

    Time frame: Baseline and up to 3 years

  10. Part 1 : Number of Participants with a MR

    The MR will be evaluated for all participants, and peripheral blood will be collected and tested for breakpoint cluster region::Abelson (BCR::ABL1/ABLIS) using real-time quantitative polymerase chain reaction performed locally and centrally with validated polymerase chain reaction technology that has a sensitivity of at least 4.5 logs. An MR is defined as follows: MR1: BCR::ABL1IS \> 1% to 10%; MR2: BCR::ABL1IS \> 0.1% to 1%; MR3 (MMR): BCR::ABL1IS \> 0.01% to 0.1%; MR4.0: BCR::ABL1IS \> 0.0032% to 0.01%; MR4.5: BCR::ABL1IS \> 0.001% to 0.0032%, MR5: ≤ 0.001%. The number of participants with a MR will be reported.

    Time frame: Baseline and up to 3 years

  11. Part 1: Number of Participants who had Best Categorical Shift in BCR-ABL1 Transcript Levels From Baseline

    The number of participants who had best categorical molecular response shift on treatment relative to baseline will be reported.

    Time frame: Baseline and up to 3 years

07

Study locations

48 of 54 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Nov 2029, 68 months after the start.

Of 26 phase 1/2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 56 and three quarters within 94. This study's planned 68 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2023
First posted
Dec 8, 2023
StartActual
Mar 26, 2024
Primary completionEst.
Nov 30, 2029
CompletionEst.
May 31, 2030
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
180→330
Oct 15, 2026
Eligibility
3 inclusion criteria edited; 1 exclusion criterion edited; 1 criterion removed
What changed in the criteria
  • RemovedMale or female participants ≥ 18 years of age at the time of signing the informed consent
Inclusion criteria
  • EditedHave an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
  • EditedHave an established cytopathologically confirmed diagnosis of breakpoint cluster region::Abelson (BCR-ABL1) positive Chronic Myeloid Leukemia (CML) in Chronic Phase
  • EditedHave received treatment with at least one prior tyrosine kinase inhibitor (TKI) and have treatment failure, suboptimal response, or treatment intolerance
Exclusion criteria
  • EditedSystemic antineoplastic therapy (including prior TKIs, interferon-alfa, therapeutic antibodies, chemotherapy) or other experimental therapy 7 days before the first dose of MK-4208/TERN-701
Oct 15, 2026
Interventions
Changed TERN-701→MK-4208. Arm changed Part 2m - 500 mg Dose→Part 2m - MK-4208 500 mg QD. Arms added: Part 1 - MK-4208 160 mg once daily (QD)·Part 1- MK-4208 320 mg QD·Part 1- MK-4208 400 mg QD·Part 1- MK-4208 500 mg QD·Part 2 - MK-4208 320 mg QD·and 4 more
All 9

Part 1 - MK-4208 160 mg once daily (QD) · Part 1- MK-4208 320 mg QD · Part 1- MK-4208 400 mg QD · Part 1- MK-4208 500 mg QD · Part 2 - MK-4208 320 mg QD · Part 2 - MK-4208 500 mg QD · Part 2m - MK-4208 320 mg twice per day (BID) · Part 2m - MK4208 500 mg BID · Part 3 - MK-4208 500 mg QD

; arms removed: Part 1- Dose Level 1 (160 mg) of TERN-701·Part 1- Dose Level 2 (320 mg) of TERN-701·Part 1- Dose Level 3 (400 mg) of TERN-701·Part 1- Dose Level 4 (500 mg) of TERN-701·Part 2 - Dose 1 (320 mg)·and 1 more
All 6

Part 1- Dose Level 1 (160 mg) of TERN-701 · Part 1- Dose Level 2 (320 mg) of TERN-701 · Part 1- Dose Level 3 (400 mg) of TERN-701 · Part 1- Dose Level 4 (500 mg) of TERN-701 · Part 2 - Dose 1 (320 mg) · Part 2 - Dose 2 (500 mg)

Oct 15, 2026
Primary outcomes
4 edited, 3 added, 2 removed
What changed in the outcomes
  • EditedPart 1 -: Incidence of Dose Limiting Toxicities during(DLTs) During the first cycleFirst Cycle of treatmentInterventionTime frame: First cycle is 28 days → Up to 28 days
  • EditedPartParts 2-, 2m and 3: Number of Participants with a Complete Hematologic Response (CHR)Time frame: up to 3 years → Baseline and up to 3 years
  • EditedPartParts 2, 2m and 3: Number of Participants with a Molecular response (MR)Time frame: up to 3 years → Baseline and up to 3 years
  • EditedPartParts 2 -, 2m and 3: Number of Participants who had Best categorical shiftCategorical Shift in BCR-ABL1 transcript levels from baselineTranscript Levels From BaselineTime frame: up to 3 years → Baseline and up to 3 years
  • AddedParts 1, 2m and 3: Number of Participants with at Least One AETime frame: Up to 3 years
  • AddedParts 1, 2m and 3: Number of Participants with at Least One Serious Adverse Event (SAE)Time frame: Up to 3 years
  • AddedParts 1, 2m and 3: Number of Participants who Discontinued Study Intervention Due to an AETime frame: Up to 3 years
  • RemovedPart 1 - Serious Adverse EventsTime frame: up to 3 years
  • RemovedPart 1 - Adverse EventsTime frame: up to 3 years
Oct 15, 2026
Secondary outcomes
11 added
What changed in the outcomes
  • AddedParts 1, 2, 2m and 3: Trough Concentration (Ctrough) of MK-4208 in PlasmaTime frame: Pre dose and post dose at predetermined time points up to 3 years
  • AddedParts 1, 2, 2m and 3: Maximum Concentration (Cmax) of MK-4208 in PlasmaTime frame: Pre dose and post dose at predetermined time points up to 3 years
  • AddedParts 1, 2, 2m and 3: Area Under the Plasma Concentration Time Curve (AUC) of MK-4208 in PlasmaTime frame: Pre dose and post dose at predetermined time points up to 3 years
  • AddedParts 1, 2, 2m and 3: Oral Clearance (CL) of MK-4208 in PlasmaTime frame: Pre dose and post dose at predetermined time points up to 3 years
  • AddedParts 1, 2, 2m and 3: Time to Maximum Concentration (Tmax) of MK-4208 in PlasmaTime frame: Pre dose and post dose at predetermined time points up to 3 years
  • AddedPart 2: Number of Participants with at Least One AETime frame: Up to 3 years
  • AddedPart 2: Number of Participants with at Least One SAETime frame: Up to 3 years
  • AddedPart 2: Number of Participants who Discontinued Study Intervention Due to an AETime frame: Up to 3 years
  • AddedPart 1: Number of Participants with a CHRTime frame: Baseline and up to 3 years
  • AddedPart 1 : Number of Participants with a MRTime frame: Baseline and up to 3 years
  • AddedPart 1: Number of Participants who had Best Categorical Shift in BCR-ABL1 Transcript Levels From BaselineTime frame: Baseline and up to 3 years
Oct 15, 2026
Contact
Study contact changed: c•••@ternspharma.com · •••5535→T•••@merck.com · •••8839. See the current contact
Oct 15, 2026
Title
A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
Oct 15, 2026
Sponsor
Terns, Inc.→Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Enrollment 180→330
    Eligibility 3 inclusion criteria edited; 1 exclusion criterion edited; 1 criterion removed
    What changed in the criteria
    • RemovedMale or female participants ≥ 18 years of age at the time of signing the informed consent
    Inclusion criteria
    • EditedHave an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
    • EditedHave an established cytopathologically confirmed diagnosis of breakpoint cluster region::Abelson (BCR-ABL1) positive Chronic Myeloid Leukemia (CML) in Chronic Phase
    • EditedHave received treatment with at least one prior tyrosine kinase inhibitor (TKI) and have treatment failure, suboptimal response, or treatment intolerance
    Exclusion criteria
    • EditedSystemic antineoplastic therapy (including prior TKIs, interferon-alfa, therapeutic antibodies, chemotherapy) or other experimental therapy 7 days before the first dose of MK-4208/TERN-701
    Primary outcomes 4 edited, 3 added, 2 removed
    What changed in the outcomes
    • EditedPart 1 -: Incidence of Dose Limiting Toxicities during(DLTs) During the first cycleFirst Cycle of treatmentInterventionTime frame: First cycle is 28 days → Up to 28 days
    • EditedPartParts 2-, 2m and 3: Number of Participants with a Complete Hematologic Response (CHR)Time frame: up to 3 years → Baseline and up to 3 years
    • EditedPartParts 2, 2m and 3: Number of Participants with a Molecular response (MR)Time frame: up to 3 years → Baseline and up to 3 years
    • EditedPartParts 2 -, 2m and 3: Number of Participants who had Best categorical shiftCategorical Shift in BCR-ABL1 transcript levels from baselineTranscript Levels From BaselineTime frame: up to 3 years → Baseline and up to 3 years
    • AddedParts 1, 2m and 3: Number of Participants with at Least One AETime frame: Up to 3 years
    • AddedParts 1, 2m and 3: Number of Participants with at Least One Serious Adverse Event (SAE)Time frame: Up to 3 years
    • AddedParts 1, 2m and 3: Number of Participants who Discontinued Study Intervention Due to an AETime frame: Up to 3 years
    • RemovedPart 1 - Serious Adverse EventsTime frame: up to 3 years
    • RemovedPart 1 - Adverse EventsTime frame: up to 3 years
    Secondary outcomes 11 added
    What changed in the outcomes
    • AddedParts 1, 2, 2m and 3: Trough Concentration (Ctrough) of MK-4208 in PlasmaTime frame: Pre dose and post dose at predetermined time points up to 3 years
    • AddedParts 1, 2, 2m and 3: Maximum Concentration (Cmax) of MK-4208 in PlasmaTime frame: Pre dose and post dose at predetermined time points up to 3 years
    • AddedParts 1, 2, 2m and 3: Area Under the Plasma Concentration Time Curve (AUC) of MK-4208 in PlasmaTime frame: Pre dose and post dose at predetermined time points up to 3 years
    • AddedParts 1, 2, 2m and 3: Oral Clearance (CL) of MK-4208 in PlasmaTime frame: Pre dose and post dose at predetermined time points up to 3 years
    • AddedParts 1, 2, 2m and 3: Time to Maximum Concentration (Tmax) of MK-4208 in PlasmaTime frame: Pre dose and post dose at predetermined time points up to 3 years
    • AddedPart 2: Number of Participants with at Least One AETime frame: Up to 3 years
    • AddedPart 2: Number of Participants with at Least One SAETime frame: Up to 3 years
    • AddedPart 2: Number of Participants who Discontinued Study Intervention Due to an AETime frame: Up to 3 years
    • AddedPart 1: Number of Participants with a CHRTime frame: Baseline and up to 3 years
    • AddedPart 1 : Number of Participants with a MRTime frame: Baseline and up to 3 years
    • AddedPart 1: Number of Participants who had Best Categorical Shift in BCR-ABL1 Transcript Levels From BaselineTime frame: Baseline and up to 3 years
    Interventions Changed TERN-701→MK-4208. Arm changed Part 2m - 500 mg Dose→Part 2m - MK-4208 500 mg QD. Arms added: Part 1 - MK-4208 160 mg once daily (QD)·Part 1- MK-4208 320 mg QD·Part 1- MK-4208 400 mg QD·Part 1- MK-4208 500 mg QD·Part 2 - MK-4208 320 mg QD·and 4 more
    All 9

    Part 1 - MK-4208 160 mg once daily (QD) · Part 1- MK-4208 320 mg QD · Part 1- MK-4208 400 mg QD · Part 1- MK-4208 500 mg QD · Part 2 - MK-4208 320 mg QD · Part 2 - MK-4208 500 mg QD · Part 2m - MK-4208 320 mg twice per day (BID) · Part 2m - MK4208 500 mg BID · Part 3 - MK-4208 500 mg QD

    ; arms removed: Part 1- Dose Level 1 (160 mg) of TERN-701·Part 1- Dose Level 2 (320 mg) of TERN-701·Part 1- Dose Level 3 (400 mg) of TERN-701·Part 1- Dose Level 4 (500 mg) of TERN-701·Part 2 - Dose 1 (320 mg)·and 1 more
    All 6

    Part 1- Dose Level 1 (160 mg) of TERN-701 · Part 1- Dose Level 2 (320 mg) of TERN-701 · Part 1- Dose Level 3 (400 mg) of TERN-701 · Part 1- Dose Level 4 (500 mg) of TERN-701 · Part 2 - Dose 1 (320 mg) · Part 2 - Dose 2 (500 mg)

    Sponsor Terns, Inc.→Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
    Contact Study contact changed: c•••@ternspharma.com · •••5535→T•••@merck.com · •••8839. See the current contact
    Title A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
    + 6 other changes: verification date, oversight details, description, conditions, design details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06163430
Responsible party
Sponsor
First posted
Dec 8, 2023
Start date
Mar 26, 2024
Primary completion
Nov 30, 2029 (estimated)
Completion
May 31, 2030 (estimated)
Last update
Oct 15, 2026

Study contacts

Toll Free Number
Contact
Trialsites@merck.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Embibatinib

Start the discussion